Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream Jan 20, 2026 07:00AM
Radiopharm Theranostics increases stake in cancer drug joint venture to 87.5% Jan 12, 2026 07:03AM
RAD Increases Ownership in Radiopharm Ventures to 87.5% Jan 12, 2026 07:00AM
Radiopharm Theranostics raises A$35 million in institutional placement, launches share buyback Oct 20, 2025 07:31AM
Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan Oct 20, 2025 07:30AM


Jul 22, 2025 09:04AM Radiopharm Theranostics adds cancer specialist to scientific advisory board
Jul 22, 2025 08:00AM Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Mar 17, 2025 08:56AM New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution
Feb 10, 2025 08:00AM New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases
Jan 10, 2025 08:00AM Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
Dec 30, 2024 08:00AM Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
Dec 20, 2024 08:00AM RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Nov 27, 2024 08:01AM Radiopharm (RADX) Achieves Nasdaq Listing of American Depositary Shares
Nov 27, 2024 08:00AM Radiopharm Achieves Nasdaq Listing of American Depositary Shares